Preservative-free influenza vaccine

Area of Science:

• Immunology
• Vaccinology

Background:

• Influenza vaccines are crucial for public health, with ongoing research into improved formulations.
• Preservatives in vaccines have been a subject of discussion regarding safety and efficacy.

Purpose of the Study:

• To evaluate the immunogenicity and safety of the preservative-free inactivated influenza vaccine, Begrivac.
• To assess the vaccine's ability to elicit an antibody response and its tolerability profile.

Main Methods:

• Prospective, single-centre, non-controlled study design.
• Influenza antibody titres were measured using the haemagglutination inhibition test.
• Safety was assessed through post-injection reactions and adverse events.

Main Results:

• Begrivac met all three European efficacy requirements for influenza vaccines.
• Adults demonstrated higher seroconversion rates and vaccination responses compared to the elderly group across multiple influenza strains.
• The majority of reported adverse events were mild, local reactions at the injection site or transient systemic symptoms.

Conclusions:

• The preservative-free formulation of Begrivac does not compromise its efficacy.
• The vaccine exhibits a favorable safety and tolerability profile.
• Begrivac is a viable option for influenza prevention, particularly for those seeking preservative-free alternatives.